Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

Additional Cerevance Presentations at AAN 2025The company presented a poster demonstrating the potential of its proprietary NETSseq platform to identify and/or validate cell-specific gene targets ...

Solengepras, the most advanced investigational treatment in Cerevance's pipeline, is an oral, non-dopaminergic therapy in Phase 3 development for Parkinson's disease. A brain-penetrant, specific ...

Takeda and venture capital group Lightstone Ventures have launched Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric ...